George T Grossberg
Overview
Explore the profile of George T Grossberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
3141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naidu A, Silverglate B, Silverglate M, Grossberg G
Expert Opin Drug Saf
. 2025 Feb;
:1-6.
PMID: 39948713
Introduction: BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) inhibitors have shown promise in treating Alzheimer's disease (AD) by reducing amyloid-beta (Aβ) production. However, clinical trials of inhibitors such as...
2.
Thussu S, Naidu A, Manivannan S, Grossberg G
Expert Rev Neurother
. 2024 Sep;
24(11):1045-1053.
PMID: 39291991
Introduction: Alzheimer's disease is the most common form of dementia worldwide. Aducanumab, a monoclonal antibody targeting amyloid-beta, became the first disease-modifying treatment for mild cognitive impairment due to Alzheimer's disease...
3.
Buck A, Rezaei K, Quazi A, Goldmeier G, Silverglate B, Grossberg G
Expert Rev Neurother
. 2024 May;
24(6):607-614.
PMID: 38785454
Introduction: Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with...
4.
Song T, Wang Y, Silverglate B, Grossberg G
Expert Opin Drug Metab Toxicol
. 2024 May;
20(6):411-417.
PMID: 38758223
Introduction: Donanemab is a humanized monoclonal antibody that significantly reduces cerebral amyloid plaques in Alzheimer's Disease (AD). It can delay disease progression and cognitive decline, making it one of the...
5.
Schiller E, Silverglate B, Grossberg G
Expert Rev Neurother
. 2024 Apr;
24(5):433-441.
PMID: 38566584
Introduction: In July 2023, the U.S. Food and Drug Administration (FDA) granted full approval to lecanemab for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and...
6.
Lee D, Slomkowski M, Hefting N, Chen D, Larsen K, Kohegyi E, et al.
JAMA Neurol
. 2023 Nov;
80(12):1307-1316.
PMID: 37930669
Importance: Agitation is a prevalent, distressing, and burdensome manifestation of Alzheimer dementia in need of an efficacious, safe, and well-tolerated treatment. Objective: To confirm the efficacy, safety, and tolerability of...
7.
Silverglate B, Gao X, Lee H, Maliha P, Grossberg G
Expert Opin Ther Targets
. 2023 Jul;
27(7):523-530.
PMID: 37475487
Introduction: Although there are several FDA-approved treatments for Alzheimer's disease (AD), only recently have disease-modifying therapies received approval for use in patients. In this narrative review, we examine the history...
8.
Khoury R, Gallop A, Roberts K, Grysman N, Lu J, Grossberg G
Expert Opin Pharmacother
. 2022 Jul;
23(11):1305-1323.
PMID: 35793398
Introduction: Alzheimer's disease (AD) is a debilitating disease, with no cure. Recently, a monoclonal antibody (aducanumab) directed toward amyloid aggregates was approved as a disease-modifying treatment (DMT) for the disease....
9.
To J, Shao Z, Gandawidjaja M, Tabibi T, Grysman N, Grossberg G
Curr Nutr Rep
. 2022 Mar;
11(2):161-171.
PMID: 35347664
Purpose Of Review: Increasing evidence points toward the importance of diet and its impact on cognitive decline. This review seeks to clarify the impact of four diets on cognition: the...
10.
Chepke C, Shaughnessy L, Brunton S, Farmer J, Rosenzweig A, Grossberg G, et al.
Int J Gen Med
. 2022 Jan;
14:10271-10280.
PMID: 34992442
The presence of hallucinations and delusions in patients with neurodegenerative disease correlates negatively with function, cognition, quality of life, and survival. When these patients still have insight, the treatment of...